@article{27b4c0fe03aa4e31935369b8af2763c5,
title = "Associations of epstein-barr virus-positive gastric adenocarcinoma with circulating mediators of inflammation and immune response",
abstract = "Epstein-Barr virus (EBV)-positive gastric adenocarcinoma exhibits locally intense inflammation but systemic manifestations are uncertain. Our study examined whether circulating mediators of inflammation and immune response differ by tumor EBV status. From a Latvian series of 302 gastric cancer cases, we measured plasma levels of 92 immune-related proteins in the 28 patients with EBV-positive tumors and 34 patients with EBV-negative tumors. Eight markers were statistically significantly higher with tumor EBV positivity: chemokine C-C motif ligand (CCL) 20 (Odds Ratio (OR) = 3.6; p-trend = 0.001), chemokine C-X-C motif ligand 9 (OR = 3.6; p-trend = 0.003), programmed death-ligand 1 (PD-L1; OR = 3.4; p-trend = 0.004), interleukin (IL)-10 (OR = 2.4; p-trend = 0.019), CCL19 (OR = 2.3; p-trend = 0.019), CCL11 (OR = 2.2; p-trend = 0.026), IL-17A (OR = 2.0; p-trend = 0.038) and CCL8 (OR = 1.9; p-trend = 0.049). Systemic responses to EBV-positive gastric cancer are characterized by alterations in chemokines and PD-L1. Profiling of these molecules may enable non-invasive diagnosis of EBV status when tumor tissue is unavailable. Our findings provide theoretical justification for clinical evaluations of immune checkpoint therapy for EBV-positive gastric cancer.",
keywords = "Chemokines, EBV, Gastric cancer, Inflammation, PD-L1",
author = "Camargo, \{M. Constanza\} and Armands Sivins and Sergejs Isajevs and Valdis Folkmanis and Dace Rudzīte and Gulley, \{Margaret L.\} and Offerhaus, \{G. Johan\} and Marcis Leja and Rabkin, \{Charles S.\}",
note = "Funding Information: This research work was supported by the ERDF project in Latvia, “H. pylori risk stratification, optimization of management and interplay with other gastric microbiota within major cancer prevention studies of international scope,” University of North Carolina Department of Pathology and U.S. National Cancer Institute (NCI) Center Core Support Grant (2P30CA016086-40) to Lineberger Comprehensive Cancer Center, and the Intramural Research Program of the U.S. NCI. Funding Information: Funding: This research work was supported by the ERDF project in Latvia, “H. pylori risk stratification, optimization of management and interplay with other gastric microbiota within major cancer prevention studies of international scope,” University of North Carolina Department of Pathology and U.S. National Cancer Institute (NCI) Center Core Support Grant (2P30CA016086-40) to Lineberger Comprehensive Cancer Center, and the Intramural Research Program of the U.S. NCI. Publisher Copyright: {\textcopyright} 2018 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2018",
month = sep,
day = "1",
doi = "10.3390/cancers10090284",
language = "English",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",
}